Selection approaches were highly heterogeneous, limiting cross-study comparability and underscoring the absence of a ...

A multi-cohort genomic and molecular dynamics study links CUL3 mutations to TP53-associated NRF2 dysregulation in EGFR-driven ...

Researchers from several major U.S. universities and ITMO University in Russia have identified a number of new driver mutations in lung cancer cells that may be responsive to genomically targeted ...

An observational study of 3.3 million research participants found that inherited EGFR T790M was associated with 25-fold higher lung cancer risk overall and more than 60-fold risk among never-smokers.

Lung cancer is the most common and deadly form of cancer worldwide. It is increasingly understood to be a complex genetic disease with different mutations that vary according to factors such as ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. People who have never smoked may still be at a much higher risk of ...

Divarasib controlled KRAS G12C-positive lung cancer longer than the currently available targeted pills, with fewer side ...

CURE spoke with Dr. Alexander Spira to learn what patients need to know about the KRAS G12C mutation and its treatment strategies. Knowledge of the KRAS G12C mutations can be very important for ...

CURE spoke with Dr. Xiuning Le during the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer. Lung cancer research has recognized the role of EGFR ...

New targeted treatment option now available in for adult patients with BRAFV600E mutant advanced non-small cell lung cancer (NSCLC)Launch follows European approval based on results from the Phase II ...

Launch expands AstraZeneca’s commitment to addressing substantial unmet need across the spectrum of EGFR-mutated lung cancer ...

Never smoked but still at risk? Dr Sunny Jain highlights the growing concern of lung cancer among women and the factors that ...